VivoSim Labs Inc (VIVS) Stock Analysis

AI analysis of VivoSim Labs Inc (VIVS)

Sell

VivoSim Labs Inc (VIVS) is not a good buy right now due to its significant financial struggles and poor technical indicators. The current price is $0.14, which is near its 52-week low of $0.14, and the stock has experienced a staggering year-to-date change of -92.45%. Additionally, the RSI is at 35.34, indicating that the stock is oversold, but this does not guarantee a price recovery. The company has reported substantial losses, with a net income of -$5,764,000 in Q4 2026 and a gross margin of 100%, but this has not translated into profitability. The main risk is the company's high volatility and lack of consistent revenue growth, as evidenced by a 20-day change of -21.15%.

Valuation Metrics

The current forward P/E ratio for VivoSim Labs Inc (VIVS) is 0.00, compared to its 5-year average forward P/E of -0.25.

Forward P/E

Strongly Overvalued

5Y Average P/E

-0.25

Current P/E

0.00

Overvalued

-0.18

Undervalued

-0.31

Forward EV/EBITDA

Strongly Undervalued

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued

0.00

Undervalued

0.00

Forward P/S

Strongly Undervalued

5Y Average P/S

23.34

Current P/S

0.00

Overvalued

31.32

Undervalued

15.36

Alphio AI Price Scenarios for VIVS

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%VIVS

$6.43

Scenario price

B

Base

Base · 50%VIVS

$4.78

Scenario price

B

Bear

Bear · 25%VIVS

$3.14

Scenario price

VIVS FAQ — answered by Alphio AI

VivoSim Labs, Inc. is a pharmaceutical and biotechnology services company, which is focused on providing testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. The Company offers partners liver and intestinal toxicology insights using its new approach methodologies (NAM) models. The Company offers liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development. It uses its proprietary technologies to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease. The Company also advances product candidates to treat inflammatory bowel disease (IBD) discovered and developed using its complex human tissue intestinal models. It operates in the Healthcare sector.

VivoSim Labs Inc (VIVS) is not a good buy right now due to its significant financial struggles and poor technical indicators. The current price is $0.14, which is near its 52-week low of $0.14, and the stock has experienced a staggering year-to-date change of -92.45%. Additionally, the RSI is at 35.34, indicating that the stock is oversold, but this does not guarantee a price recovery. The company has reported substantial losses, with a net income of -$5,764,000 in Q4 2026 and a gross margin of 100%, but this has not translated into profitability. The main risk is the company's high volatility and lack of consistent revenue growth, as evidenced by a 20-day change of -21.15%.